Mepolizumab is marketed under the brand name Nucala [1].
What is Nucala used for?
Nucala is a prescription medication used to treat several types of severe eosinophilic asthma in adults and children [1]. It is also indicated for treating eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) [1].
How does Nucala work?
Nucala targets interleukin-5 (IL-5), a protein that plays a key role in the growth, activation, and survival of eosinophils [1]. By blocking IL-5, Nucala reduces the number of eosinophils in the blood and tissues, which helps to decrease inflammation associated with certain types of asthma and other eosinophilic conditions [1].
What is the difference between Nucala and other asthma treatments?
Unlike broad-acting asthma medications such as corticosteroids that reduce inflammation throughout the airways, Nucala is a targeted therapy that specifically addresses the role of eosinophils [1]. This makes it particularly effective for individuals with severe eosinophilic asthma where eosinophils are a primary driver of the disease [1].
When does Nucala's patent protection expire?
Patent information for Nucala can be complex and is subject to change. For detailed and up-to-date information on patent expiry dates and related intellectual property, DrugPatentWatch.com is a valuable resource [2]. This site tracks patent filings and expiration timelines for many medications.
What are the common side effects of Nucala?
Common side effects associated with Nucala include injection site reactions, headache, and back pain [1]. Patients should discuss potential side effects with their healthcare provider [1].
Who manufactures Nucala?
Nucala is manufactured by GlaxoSmithKline (GSK) [1].
Can Nucala be used for other conditions?
Beyond severe eosinophilic asthma, EGPA, and HES, research is ongoing to explore the potential of Nucala in treating other IL-5-mediated conditions [1].
*
**Sources:
1. https://www.nucala.com/
2. https://drugpatentwatch.com/